News >

FDA Approves Pegfilgrastim Biosimilar

Gina Columbus @ginacolumbusonc
Published: Monday, Nov 05, 2018

The FDA has granted an approval to pegfilgrastim-cbqv (CHS-1701; Udenyca), a pegfilgrastim (Neulasta) biosimilar, for patients with cancer receiving myelosuppressive chemotherapy, according to Coherus BioSciences, Inc, the manufacturer of the agent.

In June 2018, the FDA granted approval to pegfilgrastim-jmdb (Fulphila), another pegfilgrastim biosimilar to decrease the incidence of infection by febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy.
Coherus Biosciences, Inc. U.S. FDA approves UDENYCA™ (pegfilgrastim-cbqv). Published November 2, 2018. https://bit.ly/2Rxyt8c. Accessed November 5, 2018.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Addressing Uncertainties in Oncology BiosimilarsApr 30, 20201.5
Community Practice Connections™: Show Me the Data™: Leveraging the Evidence to Optimize Applications of Biosimilars in CancerAug 30, 20201.5
Publication Bottom Border
Border Publication
x